JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M110316200 on November 5, 2001

J. Biol. Chem., Vol. 277, Issue 2, 1433-1442, January 11, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/2/1433    most recent
M110316200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, J.
Right arrow Articles by Margulies, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, J.
Right arrow Articles by Margulies, D. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Binding of the Natural Killer Cell Inhibitory Receptor Ly49A to Its Major Histocompatibility Complex Class I Ligand

CRUCIAL CONTACTS INCLUDE BOTH H-2Dd AND beta 2-MICROGLOBULIN*

Jian WangDagger , Mary C. WhitmanDagger , Kannan NatarajanDagger , José Tormo§, Roy A. Mariuzza, and David H. MarguliesDagger ||

From the Dagger  Molecular Biology Section, Laboratory of Immunology, NIAID, National Institutes of Health, Bethesda, Maryland 20892-1892, § Campus de la Universidad Autonoma de Madrid, 28049 Madrid, Spain, and  Center for Advanced Research in Biotechnology, University of Maryland Biotechnology Institute, Rockville, Maryland 20850

Received for publication, October 26, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ly49A, an inhibitory C-type lectin-like mouse natural killer cell receptor, functions through interaction with the major histocompatibility complex class I molecule, H-2Dd. The x-ray crystal structure of the Ly49A·H-2Dd complex revealed that homodimeric Ly49A interacts at two distinct sites of H-2Dd: Site 1, spanning one side of the alpha 1 and alpha 2 helices, and Site 2, involving the alpha 1, alpha 2, alpha 3, and beta 2m domains. Mutants of Ly49A, H-2Dd, and beta 2-microglobulin at intermolecular contacts and the Ly49A dimer interface were examined for binding affinity and kinetics. Although mutations at Site 1 had little affect, several at Site 2 and at the dimer interface hampered the Ly49A·H-2Dd interaction, with no effect on gross structure or T cell receptor interaction. The region surrounding the most critical residues (in H-2Dd, Asp122; in Ly49A, Asp229, Ser236, Thr238, Arg239, and Asp241; and in beta 2-microglobulin, Gln29 and Lys58) of the Ly49A·H-2Dd interface at Site 2 includes a network of water molecules, suggesting a molecular basis for allelic specificity in natural killer cell recognition.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NK1 cells provide a crucial arm of the innate immune system as they are poised to respond by cytolysis and lymphokine production to stimulation by neoplastic or infected cells (1-3). NK cell activation is regulated by a balance of activating and inhibitory signals delivered through receptors of the immunoglobulin and C-type lectin-like superfamilies, that recognize MHC-I or MHC-I-like molecules expressed on target cells (4). In resting NK cells the inhibitory signals dominate, and perturbation of normal expression of MHC-I, by viral infection or oncogenic dysregulation, leads to attenuation of the inhibitory signal and augmentation of the activating one. The best understood inhibitory NK receptor of the C-type lectin family is murine Ly49A, a type II membrane homodimer in which the structure in complex with the MHC-I ligand, H-2Dd, has been determined crystallographically (5). Direct interaction of Ly49A with H-2Dd has been demonstrated in cell adhesion and protein binding assays (6-9). In addition, biotinylated Ly49A has been employed in staining the naturally expressed H-2Dd ligand on normal cells (10, 11). Labeled tetrameric MHC-I molecules including H-2Dd bind specifically to various Ly49-expressing cells (12, 13). Although Ly49A is a member of the C-type lectin superfamily, Ly49A-mediated recognition is Ca2+- and carbohydrate-independent and is MHC-I-restricted but not peptide-specific (9, 14-16).

The crystal structure of the Ly49A·H-2Dd complex (5) indicated that the Ly49A homodimer interacts with two topographically distinct sites on H-2Dd (Fig. 1a). At Site 1, a single Ly49A subunit contacts one end of the MHC-I peptide-binding groove, involving the amino terminus of the alpha 1 helix and the carboxyl terminus of alpha 2. Site 2 is a concavity beneath the peptide-binding platform, bounded by amino acid residues of the floor of the beta  sheet of the alpha 1 and alpha 2 domains, as well as by the alpha 3 domain and the MHC-I light chain, beta 2m. This site overlaps the region where CD8alpha alpha interacts with MHC-I (5). In attempts to understand the details of the interaction of Ly49 receptors with their MHC-I ligands, several groups have analyzed binding and recognition using cells transfected with recombinant Ly49 molecules (17, 18), MHC-I mutants in transfected cells (16, 19-22), and binding of recombinant Ly49A to cells derived from different mouse inbred strains (10, 11). These studies suggest that amino acids in the "neck" region of Ly49A (17) or Ly49C (18), residues of both Site 1 of H-2Dd (10) and Site 2 (22), as well as of its peptide-binding grove (20, 21) may all contribute either directly or indirectly to the Ly49A/MHC-I interaction. In addition, two groups have reported the effects of human beta 2m on the Ly49A/MHC-I interaction (22, 23). Thus, although some evidence supports Site 1 as a primary region of interaction between MHC-I and Ly49A, other experiments are more consistent with Site 2 playing the predominant role, and some studies are inconclusive.

To resolve the issue as to whether Site 1 or Site 2 plays the major role, we have exploited a well defined biochemical system using only recombinant, highly purified molecules. Using a panel of site-directed mutants of Ly49A, H-2Dd, and beta 2m in binding assays, we have determined kinetic and equilibrium parameters quantitatively. These data, viewed in the context of the crystal structure of the Ly49A·H-2Dd complex, define not only the dominant site of interaction of Ly49A with its MHC-I ligand as Site 2, but also provide insight into the importance of homodimeric interaction in maintaining the integrity of Ly49A. Inspection of the region of intermolecular contact at Site 2 reveals important contributions from a network of water molecules coordinated by Ly49A, H-2Dd, and beta 2m residues and helps to explain the allelic specificity and peptide preference that particular members of the Ly49 family exhibit.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mutagenesis of Ly49A, H-2Dd, and Mouse beta 2m-- Mutants were generated by site-directed mutagenesis of the codons of interest to encode alanine substitutions. Using Stratagene's QuickChange Mutagenesis Kit and following the manufacturer's instructions, mutations were introduced into: 1) a cDNA construct encoding the entire extracellular region (residues 67-262) of the C57BL/6 allele of Ly49A in a bacterial expression vector (pET21a; Novagen) (9); 2) a cDNA construct encoding the mature extracellular residues of H-2Dd in pET3a (24); or 3) a murine beta 2m-encoding construct based on the C57BL/6 allele of beta 2m in pET21d (25). Mutations were confirmed by automated DNA sequencing analysis using an ABI 377 DNA sequencer and accompanying sequencing analysis software (PerkinElmer Life Sciences). Escherichia coli strain BL21(DE3) was transformed with these mutant plasmid DNAs for protein expression.

Protein Expression-- Bacteria harboring either the parental or mutant Ly49A-, H-2Dd-, or beta 2m-encoding plasmid vectors were cultured in LB broth containing 0.25 mg/ml carbenicillin and, following induction of exponentially growing cells for 2 h with isopropyl-1-thio-beta -D-galactopyranoside, were lysed with 0.5 mg/ml of hen egg white lysozyme overnight at 4 °C and then with 0.1% deoxycholate for 30 min. The resulting inclusion bodies were washed first with 0.1% deoxycholate in TE buffer (0.1 M Tris pH 8.0, 2 mM EDTA) and then extensively with TE, and they were then denatured in 6 M guanidine hydrochloride and reduced with 0.1 mM dithiothreitol. Ly49A was refolded following dilution into an arginine buffer (0.4 M L-arginine-HCl, 0.1 M Tris, pH 8, 2 mM EDTA, 3 mM reduced glutathione, and 0.3 mM oxidized glutathione). Following dialysis against 25 mM MES, pH 5.5, protein was further purified by ion exchange chromatography (Mono-S) followed by gel filtration on a Superdex 75 column. H-2Dd was prepared similarly, with refolding taking place in the presence of mouse beta 2m and either a motif (AGPARAAAL) peptide (26) or the HIV IIIB envelope gp160 peptide, P18-I10 (RGPGRAFVTI) (27, 28). Refolded proteins were further purified by size exclusion chromatography on Superdex-75 (Amersham Biosciences, Inc.).

Monoclonal Antibodies and Recombinant Protein Ligands-- Monoclonal antibodies used in BIAcore binding assays were: A1, specific for Ly49AC57BL/6 (29, 30), YE1-32, and YE1-48 (derived in rat) (31, 32), and JR9-318 (derived from Mus spretus) (33), which binds all allelic forms of Ly49A. The anti-Ly49G2 mAb 4D11 is described by Mason et al. (34). Anti-Ly49C/I-reactive SW5E6 (35) was used as control for Ly49A binding. mAbs 34-2-12 (anti-H-2Dd alpha 3 domain) and 34-5-8 (anti-H-2Dd alpha 1/alpha 2 domain) (36, 37) were from PharMingen (San Diego, CA). KP15, a mAb specific for H-2Dd bound to the HIV envelope glycoprotein-derived peptide Pro18-Ile10, has been described elsewhere (38). All antibodies were used as purified proteins. A single-chain TCR (scTCR) with specificity for H-2Dd/Pro18-Ile10 was expressed in E. coli and purified as described previously (39).

Surface Plasmon Resonance Binding Assays-- Assays for binding of Ly49A, H-2Dd, and mAbs were based on kinetic progress curves obtained with the BIAcore 2000 using methods employed previously (9, 40). In general, one ligand (either a mAb, Ly49A, or scTCR) was immobilized on a CM5 biosensor chip using standard coupling procedures, and solution phase ligand (analyte) was offered at a flow rate of 10 µl/min. All binding experiments were performed at 25 °C. A mock-coupled surface that was activated and blocked but had no protein immobilized was always included as a control for nonspecific binding. When Ly49A mutants were evaluated, a Ly49A wild type-coupled surface was included on the same chip for direct comparison. Kinetic data were collected and analyzed using BIAevaluation 3.1 to calculate kinetic association and dissociation rate constants and equilibrium constants for dissociation. In all cases the potential for sequential deterioration of the integrity of the solid phase ligand was evaluated periodically with appropriate controls introduced throughout the run. Binding parameters obtained by kinetic analysis were compared with equilibrium parameters calculated in parallel and were always internally consistent.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interface Mutants of the Ly49A Homodimer-- To evaluate the contribution of particular residues of Ly49A to recognition by H-2Dd, as well by specific monoclonal antibodies (mAbs), we made individual alanine substitutions at those positions that, in the crystal structure, appeared crucial to either the homodimeric interaction or the interaction between H-2Dd and Ly49A (Fig. 1). Six Ly49A interface residues, Tyr142, Trp143, Phe144, Tyr146, Leu188, and Val189 were mutated, and the bacterially expressed mutant proteins were tested for binding to bacterially expressed H-2Dd as well as to a panel of anti-Ly49 mAbs. Although several mutants showed decreased binding to some of the mAbs tested, all preserved the capacity to interact with several at levels at least 50% that of controls (Fig. 2a). Binding to 4D11, which primarily recognizes Ly49G2 and has weak activity on Ly49A, was lower for mutants at positions 142, 143, 146, and 189. Interestingly, 4D11 reactivity was greater for mutants at positions 144 and 188. Significantly, mutation at positions 142, 143, 146, and 189 each revealed decreased binding to either of the H-2Dd preparations (Fig. 2b). These results suggest that the integrity of the homodimer is important for binding to the MHC-I ligand and also influences binding by some mAbs.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Location of contacts between Ly49A and H-2Dd. a, a ribbon diagram of the structure of the Ly49A·H-2Dd complex (Protein Data Bank code 1qo3) showing sites of interaction. These are referred to as Site 1, Site 2, and Ly49A homodimer interface (labeled only on one dimer). The subunit designations are: A, H-2Dd heavy chain; B, beta 2m; C, Ly49A subunit at Site 1; D, dimeric partner of C; E, symmetry-related Ly49A subunit C; F, major Ly49A subunit interacting at Site 2. The Calpha atoms of residues of the homodimer interface (orchid), Site 2 alone (magenta), and Sites 1 and 2 (orange-red) are indicated as space-filled spheres. b, Ly49A amino acid sequence and location of residues selected for mutagenesis. The amino acid sequence of Ly49AC57BL/6 is shown with the transmembrane region (amino acids 45-66) and the lectin-like domain (amino acid 141-262) enclosed in boxes. Secondary structure elements are labeled, and the positions of site-directed mutants are indicated: interface contacts of the homodimer (filled circles, orchid), Site 1 and Site 2 (orange-red downward arrows), and Site 2 unique (magenta upward arrows).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Binding of mAbs and H-2Dd to Ly49A and its site-directed mutants. a, from 4200 to 6000 resonance units of Ly49A and the indicated mutant proteins were coupled to biosensor chips and tested for binding to different specific mAbs. b, Ly49A mutants were tested for binding to H-2Dd/motif and H-2Dd·Pro18-Ile10 complexes at a concentration of 6.5 µM. The Relative Binding, corrected for background binding to a mock-coupled surface and for level of coupling of the solid phase reagent, was compared with binding to a wild type Ly49A surface and was calculated as follows.
<UP>RB</UP>=<FR><NU><FENCE>(<UP>RU</UP><SUB><UP>bound to Ly49A mutant</UP></SUB>−<UP>RU<SUB>bound to mock</SUB></UP>)<UP>/RU</UP><SUB><UP>Ly49A mutant coupled</UP></SUB></FENCE></NU><DE><FENCE>(<UP>RU</UP><SUB><UP>bound to Ly49A WT</UP></SUB>−<UP>RU<SUB>bound to mock</SUB></UP>)<UP>/RU</UP><SUB><UP>Ly49A WT coupled</UP></SUB></FENCE></DE></FR>
Resonance unit (RU) levels are at steady state. Relative binding (RB) of Ly49A wild type therefore = 1. Open bar, Ly49A wild type (WT); solid bar, control mutant S113A; back-slashed bar, interface mutants; gray bar, Site 2 mutants alone; forward slashed bar, Site 1 and Site 2 mutants. c, relative binding of Ly49A mutants to mAbs and to H-2Dd was calculated as described above. JR9-318, a mAb that binds several Ly49 molecules, was derived from M. spretus, and we might expect the Ly49 molecules of this strain to lack Lys224. We also tested SW5E6, which recognizes Ly49C and Ly49I but not Ly49A (54). In surface plasmon resonance analysis SW5E6 failed to bind Ly49A and also showed no binding to the full panel of Ly49A mutants (data not shown).

Site 2 and Site 1, 2 Mutants of Ly49A-- Next, we examined mutants of Ly49A at H-2Dd contact sites. However, no contact residues of Ly49A are unique to Site 1, and therefore any mutation would either include both Sites 1 and 2 or be unique to Site 2. We first studied mutants at Site 2, the interface between Ly49A and H-2Dd that involves Ly49A and all three domains of H-2Dd as well as its light chain, beta 2m (Fig. 1a). For H-2Dd binding, point mutations generally either improved binding (N203A and K224A) or impaired binding significantly (S236A, T238A, and R239A). S236A and R239A showed an undetectable level of binding to H-2Dd, and T238A quantitatively reduced binding by about 9-fold (KD increasing from 1.82 to 15.9 µM largely as a result of kd increasing from 0.063 to 0.363 s-1 (Fig. 3b)). The behavior of the triad of Ser236, Thr238, and Arg239 clearly indicates the importance of Site 2 interactions in H-2Dd binding. Binding to a panel of mAbs indicated that the overall integrity of the mutants was preserved and also allowed mapping of epitopes recognized by particular mAbs (Fig. 2). Mutants of N203A, K224A, S236A, T238A, and R239A revealed differences in binding to some of the mAbs. In particular, N203A showed augmented binding to A1, YE1/32, and YE1/48, had no effect on binding to JR9-318, and showed absolutely no binding to 4D11. K224A reduced binding to A1, YE1/48, and JR9-318 and increased binding to YE1/32. Mutants S236A, T238A, and R239A modestly decreased binding to A1, and R239A increased binding to YE1/32, YE1/48, and 4D11.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   H-2Dd binding to Ly49A mutants. a, H-2Dd·motif and H-2Dd·P18-I10 were injected at five different concentrations ranging from 0.5 to 8 µM in 2-fold increments over biosensor surfaces coupled with different Ly49A mutants. Each row represents a binding assay performed on different flow cells of the same CM5 chip. Because the binding patterns of H-2Dd·motif and H-2Dd·Pro18-Ile10 preparations were similar, but the level of H-2Dd·Pro18-Ile10 binding was lower, we show only H-2Dd·motif-binding curves. b, experimental sensorgram data were obtained from binding curves of experiments similar to panel a, and kinetic evaluation was performed using BIAevaluation 3.1. Analysis employed a 1:1 binding model that included a correction for drifting base line. The different groups represent five independent experiments using different biosensor chips. t1/2 was calculated according to the relationship t1/2 = 0.693/kd. ND, nondetectable; WT, wild type.

We then analyzed seven mutants that represented contacts at both Sites 1 and 2: D229A, D241A, N242A, D246A, Q247A, V248A, and F249A (Figs. 1-3). D229A, although it revealed little or no effect on binding of any of the mAbs, eliminated interaction with H-2Dd. D241A, which profoundly reduced binding to A1 but had little effect on any other mAb, also affected binding to H-2Dd, most significantly with an increase in the kd from 0.054 to 0.363 s-1 (Fig. 3). N242A modestly reduced binding to YE1/32 and 4D11 and also impeded interaction with H-2Dd. D246A, which adversely affects binding of YE1/32 and 4D11, also showed quantitative effects on binding to H-2Dd. Other mutations of residues that structurally contribute at both Sites 1 and 2, Q247A and F249A, did not impede mAb binding and augmented it in some cases. V248A impaired recognition by YE1/32. These three mutants showed quantitative effects on binding to H-2Dd/P18-I10 but less pronounced effects when assayed with H-2Dd·motif complexes. The most consistent of the effects observed was with F249A, which showed a slight increase in ka, a marked (more than 5-fold) increase in the kd, and a 5-fold increase in KD (Fig. 3b).

Surface Representation of Ly49A Site 2 and Site 1, 2 Mutant Effects-- To visualize the location of those Ly49A residues that influence H-2Dd and mAb interaction, we generated a surface representation of their effect on binding (Fig. 4; Ly49A interface mutants are not seen in such a display). Mutations that adversely affected binding are colored in red, orange, yellow, and green, whereas those that improved binding, presumably by eliminating a negative effect, are depicted in light blue and blue. The residues that most affected A1 binding (Lys224, Asp241, and Arg239) form a contiguous patch on the surface of the molecule (Fig. 4a). Residues Asp229, Ser236, and Thr238 neighbor this region, and it is straightforward to imagine that the antibody-combining site of A1 could overlay this set of residues on one monomer of the Ly49A homodimer. A1 is an alloantibody raised in BALB/c mice against Ly49AC57BL/6 (29). Allelic differences between Ly49ABALB/c and Ly49AC57BL/6 in the region where the Ly49AC57BL/6 structure is known are at positions 187 and 238 (where Ly49AC57BL/6 has Gln and Thr, respectively, and Ly49ABALB/c has His and Ile). Residue 187 lies adjacent to residue 238 on the surface of Ly49A. In contrast to those residues in which mutation adversely affected the binding of A1, mutants N203A, Q247A, V248A, and F249A improved binding by A1.


View larger version (76K):
[in this window]
[in a new window]
 
Fig. 4.   Molecular surface representation of Ly49A mutations affecting binding by H-2Dd and mAb. Ly49A Site 2 and Site 1, 2 mutants with different binding effects were visualized in a surface representation of the structure of Ly49A. The binding of A1 (a), YE1/32 (d), YE1/48 (c), JR9-318 (f), and H-2Dd/motif (b and e) is based on the BIAcore binding analysis as shown in Fig. 2. This illustration was rendered with GRASP 1.3.6 (55). The extent of binding of each of the alanine mutants is color-coded according to the values given in the legend for Fig. 2c. The following color scale was used, with red representing the lowest level of binding and blue the highest: red, relative binding <=  0.05; orange, 0.05 < relative binding <=  0.1; yellow, 0.1 < relative binding <=  0.5; green, 0.5 < relative binding <=  1.0; light blue, 1.0 < relative binding <=  1.5; blue, 1.5 < relative binding <=  2.0.

The binding of three other antibodies, YE1/48, YE1/32, and JR9-318, to the panel of mutants reveals different characteristics. The only mutation that adversely affects binding of YE1/48 is K224A (Fig. 4c); YE1/32 is most affected by D246A (Fig. 4d); and JR9-318 is most dependent on K224 (Fig. 4f). These results suggest that YE1/32 interacts more with residues on the "side" of the Ly49A molecule than with those on the "top."

The surface region that most affects H-2Dd binding is a large area that extends from Asp246 across the top of the molecule that includes Gln247, Val248, and Phe249 as well as a distinct surface consisting of Asp229, Ser236, Thr238, Arg239, Asp241, and Asn242 (Fig. 4, b and e). In addition to the adverse effects of mutation of any of the residues in this patch, mutation of Asn203 and Lys224 to alanine improves the binding to H-2Dd molecules. Thus, the focus of H-2Dd binding is on Arg239 and the surrounding residues located along the top of Ly49A.

The Importance of Site 2 Mutants of H-2Dd and beta 2m-- Although the behavior of Ly49A mutants S236A, T238A, and R239A strongly suggested that Site 2 was the major focus of the Ly49A/H-2Dd interaction, other data, including the analysis of polymorphic MHC-I residues in different mouse strains and the behavior of a single H-2Dd mutation of I52M, had suggested that Site 1 was important (10). To clarify this issue, we tabulated the number of atomic contacts between those residues that seemed to be most involved in binding to H-2Dd (Table I). We looked closely at the contacts made by Ly49A residues Asp229, Ser236, Thr238, Arg239, Asp241, Asn242, Gln247, Val248, and Phe249 at either Site 1 or Site 2. For Site 1 contacts, Gln247, Val248, and Phe249 made 18 atomic contacts with residue Gln54 of H-2Dd, and residue Asp229 made 10 contacts with H-2Dd residue Arg169. For Site 2 contacts, the greatest number (23) were made by Ly49A residues Ser236, Thr238, and Arg239 to Asp122 of H-2Dd. These contacts are specifically between the "F" subunit of Ly49A and H-2Dd. Ly49A residues Thr238, Arg239, and Asp241 are ambiguous, however, in that those residues in the "E" subunit (Fig. 1a and Table I) also make contact with H-2Dd residues Tyr85 (8) and Asn86 (10). Residues Gln247, Val248, and Phe249 of Ly49A made 21 contacts with beta 2m residue Gln29; and residues Asp229, Arg239, Asp241, and Asn242 of Ly49A made 20 contacts with beta 2m residue Lys58.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Atomic contacts between Ly49A and H-2Dd residues
The number of atomic contacts between the indicated amino acids was tabulated from the crystal structure of Ly49A·H-2Dd using QUANTA 2000 (Molecular Simulation, Inc.).

To test the contribution to binding of these potential contact regions, we produced alanine mutations at all seven positions: two at Site 1 of the H-2Dd heavy chain (Q54A and R169A); three at Site 2 (Y85A, N86A, and D122A); and two at the beta 2m contact (Q29A and K58A). In addition, a non-contact mutant in H-2Dd, S246A, was generated as a control. Each of these eight mutants in parallel with a parental H-2Dd·motif peptide complex was tested by surface plasmon resonance for binding to Ly49A. The sensorgrams and the steady state levels of binding are plotted as a function of analyte concentration in Fig. 5. The mutational analysis of H-2Dd and beta 2m clearly implicates Site 2 as the major determinant of the Ly49A·H-2Dd binding interaction: H-2Dd mutant D122A and beta 2m mutants Q29A and K58A had profound effects on binding to Ly49A. (In addition, these two beta 2m mutants exerted no effect on the binding of a beta 2m-dependent mAb, S19.8, over a wide range of concentration. S19.8 also showed concentration-dependent inhibition of binding of H-2Dd to Ly49A even when the H-2Dd was complexed with either of the two beta 2m mutants (data not shown).) In contrast to the effects of Site 2 mutants of H-2Dd, those at Site 1, Q54A and R169A, showed little effect on binding. Two mutants at the periphery of Site 2, Y85A and N86A, and the S246A control showed only a small quantitative effect.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   H-2Dd and beta 2m mutant binding to Ly49A. The interactions between mutants of H-2Dd, beta 2m, and wild type Ly49A were measured in the BIAcore binding assay. Ly49A and mAbs specific for H-2Dd were immobilized on a CM5 chip as described under "Experimental Procedures." Wild type (WT) H-2Dd or its mutants refolded with motif peptide were measured at concentrations from 0.156 to 10 µM in 2-fold increments. Resonance unit (RU) values are corrected for background binding. a and b, data from two different experiments. c and d, dose-dependent response comparison of binding of different H-2Dd mutants and beta 2m mutants to Ly49A. All preparations were tested in parallel for binding to anti-H-2Dd mAb to confirm the concentration as determined by UV absorbance and the preservation of serological activity (data not shown).

Although H-2Dd mutant D122A and beta 2m mutants Q29A and K58A severely reduced binding to Ly49A, they retained the ability to bind to H-2Dd-specific mAbs 34-35-8 and 34-2-12 (data not shown). To eliminate the possibility that these mutations may have distorted either the peptide binding site or the TCR binding site of the molecule, we tested their ability to interact with both an H-2Dd/Pro18-Ile10-restricted specific recombinant scTCR and with an MHC-restricted, peptide-specific mAb, KP15 (38). As shown in Fig. 6, the three mutants and the parental H-2Dd/Pro18-Ile10 bind both the scTCR and KP15 equivalently. These results reinforce the view that the Ly49A binding site on H-2Dd is distinct from that of the TCR.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   Binding of different H-2Dd·peptide/beta 2m complexes to scTCR. H-2Dd mutant D122A and beta 2m mutants Q29A and K58A, which were assembled with parental H-2Dd and with peptide Pro18-Ile10, were analyzed in a dose-dependent manner for binding to: a, scTCR, 0.6-10 µM; b, mAb KP15, 0.015-0.5 µM; c, Ly49A, 0.6-20 µM (these were also compared with H-2Dd/motif binding in all cases). All preparations were also tested for binding to mAbs 34-2-12 and 34-5-8 in a similar fashion (data not shown).

To explain the profound effects exerted by mutation of H-2Dd D122A, as well as beta 2m Q29A and K58A, we returned to a close inspection of the interface of H-2Dd with Ly49A at Site 2 (Fig. 7). In particular, we have included the water molecules at this interface. The region that surrounds residue Asp122 of H-2Dd reveals not only the proximity of the side chains of residues Ser236, Thr238, and Arg239 of Ly49A but also at least seven water molecules that are involved in this interface (Fig. 7b). The beta 2m residue Lys58, which is highly conserved among species, interacts with Asp229, Asp241, and Asn242 of Ly49A amid a network of water molecules that also coordinate with the side chain of H-2Dd residue Arg6 as well as Arg239 (Fig. 7c). Continuing this general trend, beta 2m residue Gln29 (the Gln is unique to mouse beta 2m) not only interacts with its contact residues Gln247, Val248, and Phe249 on Ly49A but also interacts with a number of waters in this vicinity (Fig. 7d).


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 7.   H-2Dd residue Asp122 and beta 2m residues Gln29 and Lys58 interact with Ly49A at Site 2. Interactions of residues in H-2Dd·Ly49A complex (Protein Data Bank code 1qo3) were illustrated with MOLSCRIPT (56) and rendered with Raster3d (42). a, interaction between Ly49A (F domain), H-2Dd, and beta 2m mutants at Site 2. b, side-by-side stereo view of network of interactions of H-2Dd residue Asp122 and Ly49A residues Ser236, Lys237, Thr238, and Arg239 in the presence of water molecules. Asp122 of H-2Dd contacts directly with Ser236, Thr238, and Arg239 of Ly49A through hydrogen bonds. c, side-by-side stereo view of network of beta 2m residue Lys58 with Ly49A residues Asp229, Asp241, and Asn242 in the presence of water molecules. d, side-by-side stereo view of network of beta 2m residue Gln29 with Ly49A residues Gln247, Val248, and Phe249 in the presence of water molecules. Dashed lines indicate hydrogen bonds. Other atomic contacts are not explicitly shown. Yellow, H-2Dd; blue, Ly49A; lavender, beta 2m; orange spheres, water molecules.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our mutational analysis of the binding of Ly49A, H-2Dd, and beta 2m mutants leads to two major conclusions: that the primary binding site of H-2Dd employed by Ly49A is at Site 2, a large surface area that involves contacts from the floor of the peptide-binding groove of the MHC-I and residues from beta 2m; and that integrity of the Ly49A homodimer is critical for preservation of MHC-I binding. The effect of mutation of the homodimeric interface residues Tyr142, Trp143, Tyr146, and Val189 in reducing binding to H-2Dd as well as the augmentation of binding by mutations of Phe144 and Leu188 suggest that the structure of the surface that contacts H-2Dd is influenced by the nature of the homodimerization. These results are of particular importance when we consider the three-dimensional structure and mode of dimerization of NK receptors and related molecules. As found previously (41), the dimer interfaces of Ly49A, NKG2D, and CD69 are highly conserved, although in Ly49A it is somewhat asymmetric, whereas NKG2D and CD69 show clear symmetry. The recently determined structure of Ly49I indicates that even within the Ly49 family there is considerable flexibility in the dimerization, because in this molecule the alpha 2 helix is not involved in the dimer interface.2 These NK receptor domains dimerize differently from other more distantly related members of the C-type lectin family such as tunicate lectin and coagulation factor IX binding protein. In an evaluation of the binding of Ly49CC57BL/6 and Ly49IC57BL/6 to various MHC-I molecules in a cell agglutination assay, Lian et al. (18) observed that mutation of Tyr146 (the position equivalent to Tyr142 of Ly49A) of Ly49C to the histidine found in the closely related Ly49I resulted in reduced binding to H-2s and H-2b cell lines as well to an H-2Dd transfectant. These results suggest that variability in the mode of dimerization influences allelic specificity of Ly49 family members.

The importance of Site 2 is indicated by the effect of mutations in Ly49A unique to Site 2 (in particular residues Ser236, Thr238, and Arg239) as well as by mutation of H-2Dd (Asp122) (Fig. 7b) and beta 2m (Gln29 and Lys58 (Fig. 7, d and c)). Ly49A is unique among NK receptors of either the Ig-like or C-type lectin-like families in its utilization of the beta 2m subunit as part of its binding site. A mutational analysis of H-2Dd, based on transfection and agglutination and functional assays, indicated an important role for residues Arg6, Asp122, and Lys243 of H-2Dd (22), and the importance of species differences in beta 2m has been reported (22, 23). Our results add unequivocal data indicating the critical importance of the two major contact residues of beta 2m. This analysis also implicates beta 2m as a spatial transducer of subtle structural changes that occur either in the peptide-binding groove or in other parts of the alpha 1alpha 2 unit of the MHC heavy chain. The disposition of beta 2m with respect to the heavy chain varies markedly in different crystal structures (24, 43, 44), and the stability of the MHC/beta 2m interaction is affected by amino acid substitutions in the peptide-binding groove (45). The exquisite sensitivity of Ly49A binding to substitution of either of the two major beta 2m contact residues, Gln29 or Lys58, explains the observed effects of substitution of bovine or human beta 2m in NK recognition (22, 23), because position Gln29 is unique to murine beta 2m, whereas human and bovine variants have glycine. The effect of beta 2m dislocation at the Site 2 interface explains the behavior of two mutations of H-2Dd, D29N and R35A, that affect Ly49A binding without direct involvement of the Site 2 interface (21). Mutant D29N would be expected to have an indirect effect on beta 2m binding because it interacts primarily with H3 of H-2Dd and only indirectly with beta 2m residue Arg228. Residue Arg35 is involved in hydrogen bonds to beta 2m M54 backbone oxygen as well as to H-2Dd E32. Thus, mutation of Arg35 to Ala would be expected to change the affinity of the MHC heavy chain for beta 2m and distort the disposition of this subunit, thereby altering the interaction with Ly49A. Several other substitutions of H-2Dd that do not make direct contact with either Ly49A or beta 2m have been studied, and their behaviors may be explained by similar distant effects. In particular, the double mutant S73W,D156Y, comprising residues that line the peptide-binding groove, has been shown to have functional effects on NK recognition (20), and the double mutants D77S,A99F and N30D,A99F as well as the triple mutant N30D,D77S,A99F showed reduced binding in an Ly49A tetramer staining assay (21). Residues Ser73, Asp77, Ala99, and Asp156 play a role in peptide interaction and thus are likely to contribute to the stability of the interaction with beta 2m, thereby affecting the interaction with Ly49A. The nature of the N30D substitution, which seems synergistic with substitution of peptide binding cleft residues, probably is due to the role that N30D plays in the interaction with Ly49A via distant interaction with residue R228 of beta 2m. In addition to these experiments with mutant H-2Dd and beta 2m, our earlier studies examining the behavior of a single-chain beta 2m/H-2Dd molecule in NK cell recognition are also consistent with Ly49A interacting primarily with a site distinct from that of the TCR and subject to inhibition by the peptide linker extending from the carboxyl terminus of beta 2m to the amino terminus of H-2Dd (10, 46). Because Ly49G2, a molecule related to Ly49A in both sequence and in its ability to interact with H-2Dd, also is incapable of interacting with the single-chain beta 2m/H-2Dd molecule (46), it is likely that Ly49G2 binds H-2Dd at the same site as Ly49A. (Comparison of amino acid sequences of Ly49AC57BL/6 and Ly49G2C57BL/6 reveals that the residues that contact Asp122 of H-2Dd and Lys58 of beta 2m in the Ly49A complex are conserved, whereas those that interact with the conserved Gln29 of beta 2m are polymorphic.)

The analysis of the regions of importance in Site 2 recognition clearly implicates the organization of water molecules in this large and imperfect interface in mediating the interaction between Ly49A and H-2Dd (Fig. 7). We speculate that the binding specificity of the Ly49 molecules for their MHC/peptide ligands is influenced by a water network exemplified in the Ly49A·H-2Dd structure by residues Asp122 of H-2Dd with Ly49A·residues Ser236, Lys237, Thr238, and Arg239; Lys58 of beta 2m along with Arg6 of H-2Dd and Asp229, Arg239, Asp241, and Asn242 of Ly49A; and Gln29 of beta 2m with Asp59 of beta 2m, and Gln247, Val248, and Phe249 of Ly49A. Since the description of an important role for water in the carbohydrate specificity of the L-arabinose-binding protein (47), there has been considerable interest in the contribution of water to ligand specificity (48). Recently water has been shown to be important in the specific binding of peptides to MHC molecules (49-53).

The accumulation of the mutational evidence clearly reveals effects of H-2Dd residue Asp122 and beta 2m residues Gln29 and Lys58 on Ly49A binding. These effects seem to be local rather than global, because the TCR binding site of the H-2Dd·Pro18-Ile10 complex was preserved both for direct interaction with a cognate TCR and for binding by an MHC-restricted, peptide-specific mAb.

In summary, our mutational analysis of Ly49A has permitted the localization not only of the sites bound by each of a panel of mAbs but has also demonstrated conclusively the importance of the homodimer interface and has localized the critical site of interaction between Ly49A, H-2Dd, and beta 2m to Site 2, a region that potentially overlaps with the CD8 binding site. The strength of this interaction and the lack of more than a 3-fold effect of any of the mutants at Site 1 tested to date suggest that the Site 2 interaction functions in the recognition between the NK cell and the antigen-presenting cell, a trans mode, although it does not eliminate the possibility of cis interactions between molecules expressed on the NK cell. Further understanding of the quantitative contributions of the redistribution of water as binding takes place will require careful thermodynamic measurements under conditions that vary the activity of water as solvent.

    ACKNOWLEDGEMENTS

We thank W. M. Yokoyama (Washington University, St. Louis, MO) for providing hybridoma cells and encouragement. We thank J. Dorfman and M. Lenardo for their comments on the manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants AI47900 and GM52801 (to R. A. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This paper is dedicated to the memory of José Tormo, colleague and friend.

|| To whom correspondence should be addressed: Molecular Biology Section, LI/NIAID, Bldg. 10, Rm. 11N311, National Institutes of Health, Bethesda, MD 20892-1892. Tel.: 301-496-6429; Fax: 301-496-0222; E-mail: dhm@nih.gov.

Published, JBC Papers in Press, November 5, 2001, DOI 10.1074/jbc.M110316200

2 N. Dimasi, M. W. Sawicki, L. N. Reineck, Y. Li, K. Natarajan, D. H. Margulies, and R. A. Mariuzza, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: NK, natural killer; beta 2m, beta 2-microglobulin; mAb, monoclonal antibody; MHC, major histocompatibility complex; TCR, T cell receptor; scTCR, single-chain T cell receptor; HIV, human immunodeficiency virus; MES, 2-(N-morpholino)ethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather, T. P. (1999) Annu. Rev. Immunol. 17, 189-220
2. Lanier, L. L. (1998) Annu. Rev. Immunol. 16, 359-393
3. Yokoyama, W. M. (1999) in Fundamental Immunology (Paul, W. E., ed), 4th Ed. , pp. 575-603, Lippincott-Raven Publishers, Philadelphia
4. Kärre, K. (1997) Immunol. Rev. 155, 5-9
5. Tormo, J., Natarajan, K., Margulies, D. H., and Mariuzza, R. A. (1999) Nature 402, 623-631
6. Daniels, B. F., Karlhofer, F. M., Seaman, W. E., and Yokoyama, W. M. (1994) J. Exp. Med. 180, 687-692
7. Brennan, J., Mager, D., Jefferies, W., and Takei, F. (1994) J. Exp. Med. 180, 2287-2295
8. Kane, K. P. (1994) J. Exp. Med. 179, 1011-1015
9. Natarajan, K., Boyd, L. F., Schuck, P., Yokoyama, W. M., Eilat, D., and Margulies, D. H. (1999) Immunity 11, 591-601
10. Chung, D. H., Natarajan, K., Boyd, L. F., Tormo, J., Mariuzza, R. A., Yokoyama, W. M., and Margulies, D. H. (2000) J. Immunol. 165, 6922-6932
11. Matsumoto, N., Tajima, K., Mitsuki, M., and Yamamoto, K. (2001) Int. Immunol. 13, 615-623
12. Mehta, I. K., Smith, H. R., Wang, J., Margulies, D. H., and Yokoyama, W. M. (2001) Cell. Immunol. 209, 29-41
13. Hanke, T., Takizawa, H., McMahon, C. W., Busch, D. H., Pamer, E. G., Miller, J. D., Altman, J. D., Liu, Y., Cado, D., Lemonnier, F. A., Bjorkman, P. J., and Raulet, D. H. (1999) Immunity 11, 67-77
14. Orihuela, M., Margulies, D. H., and Yokoyama, W. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11792-11797
15. Correa, I., and Raulet, D. H. (1995) Immunity 2, 61-71
16. Matsumoto, N., Ribaudo, R. K., Abastado, J. P., Margulies, D. H., and Yokoyama, W. M. (1998) Immunity 8, 245-254
17. Brennan, J., Mahon, G., Mager, D. L., Jefferies, W. A., and Takei, F. (1996) J. Exp. Med. 183, 1553-1559
18. Lian, R. H., Li, Y., Kubota, S., Mager, D. L., and Takei, F. (1999) J. Immunol. 162, 7271-7276
19. Sundbäck, J., Nakamura, M. C., Waldenstrom, M., Niemi, E. C., Seaman, W. E., Ryan, J. C., and Kärre, K. (1998) J. Immunol. 160, 5971-5978
20. Waldenstrom, M., Sundbäck, J., Olsson-Alheim, M. Y., Achour, A., and Kärre, K. (1998) Eur. J. Immunol. 28, 2872-2881
21. Matsumoto, N., Yokoyama, W. M., Kojima, S., and Yamamoto, K. (2001) J. Immunol. 166, 4422-4428
22. Matsumoto, N., Mitsuki, M., Tajima, K., Yokoyama, W. M., and Yamamoto, K. (2001) J. Exp. Med. 193, 147-158
23. Michaelsson, J., Achour, A., Rolle, A., and Kärre, K. (2001) J. Immunol. 166, 7327-7334
24. Li, H., Natarajan, K., Malchiodi, E. L., Margulies, D. H., and Mariuzza, R. A. (1998) J. Mol. Biol. 283, 179-191
25. Shields, M. J., Moffat, L. E., and Ribaudo, R. K. (1998) Mol. Immunol. 35, 919-928
26. Corr, M., Boyd, L. F., Padlan, E. A., and Margulies, D. H. (1993) J. Exp. Med. 178, 1877-1892
27. Kozlowski, S., Corr, M., Takeshita, T., Boyd, L. F., Pendleton, C. D., Germain, R. N., Berzofsky, J. A., and Margulies, D. H. (1992) J. Exp. Med. 175, 1417-1422
28. Takeshita, T., Takahashi, H., Kozlowski, S., Ahlers, J. D., Pendleton, C. D., Moore, R. L., Nakagawa, Y., Yokomuro, K., Fox, B. S., Margulies, D. H., et al.. (1995) J. Immunol. 154, 1973-1986
29. Nagasawa, R., Gross, J., Kanagawa, O., Townsend, K., Lanier, L. L., Chiller, J., and Allison, J. P. (1987) J. Immunol. 138, 815-824
30. Yokoyama, W. M., Jacobs, L. B., Kanagawa, O., Shevach, E. M., and Cohen, D. I. (1989) J. Immunol. 143, 1379-1386
31. Takei, F. (1983) J. Immunol. 130, 2794-2797
32. Takei, F., Brennan, J., and Mager, D. L. (1997) Immunol. Rev. 155, 67-77
33. Roland, J., and Cazenave, P. A. (1992) Int. Immunol. 4, 699-706
34. Mason, L. H., Ortaldo, J. R., Young, H. A., Kumar, V., Bennett, M., and Anderson, S. K. (1995) J. Exp. Med. 182, 293-303
35. Sentman, C. L., Hackett, J., Jr., Kumar, V., and Bennett, M. (1989) J. Exp. Med. 170, 191-202
36. Ozato, K., Mayer, N., and Sachs, D. (1982) Transplantation 34, 113-120
37. Margulies, D. H., Evans, G. A., Ozato, K., Camerini-Otero, R. D., Tanaka, K., Appella, E., and Seidman, J. G. (1983) J. Immunol. 130, 463-470
38. Polakova, K., Plaksin, D., Chung, D. H., Belyakov, I. M., Berzofsky, J. A., and Margulies, D. H. (2000) J. Immunol. 165, 5703-5712
39. Plaksin, D., Polakova, K., McPhie, P., and Margulies, D. H. (1997) J. Immunol. 158, 2218-2227
40. Corr, M., Slanetz, A. E., Boyd, L. F., Jelonek, M. T., Khilko, S., al-Ramadi, B. K., Kim, Y. S., Maher, S. E., Bothwell, A. L., and Margulies, D. H. (1994) Science 265, 946-949
41. Sawicki, M. W., Dimasi, N., Natarajan, K., Wang, J., Margulies, D. H., and Mariuzza, R. A. (2001) Immunol. Rev. 181, 52-65
42. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524
43. Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., and Wilson, I. A. (1992) Science 257, 919-927
44. Madden, D. R. (1995) Annu. Rev. Immunol. 13, 587-622
45. Ribaudo, R. K., and Margulies, D. H. (1995) J. Immunol. 155, 3481-3493
46. Chung, D. H., Dorfman, J., Plaksin, D., Natarajan, K., Belyakov, I. M., Hunziker, R., Berzofsky, J. A., Yokoyama, W. M., Mage, M. G., and Margulies, D. H. (1999) J. Immunol. 163, 3699-3708
47. Quiocho, F. A., Wilson, D. K., and Vyas, N. K. (1989) Nature 340, 404-407
48. Ladbury, J. E. (1996) Chem. Biol. 3, 973-980
49. Ceman, S., Wu, S., Jardetzky, T. S., and Sant, A. J. (1998) J. Exp. Med. 188, 2139-2149
50. Gurlo, T., Meng, W. S., Bui, H. H., Haworth, I. S., and von Grafenstein, H. (1999) Immunol. Lett. 70, 139-141
51. McFarland, B. J., Beeson, C., and Sant, A. J. (1999) J. Immunol. 163, 3567-3571
52. Wilson, N., Fremont, D., Marrack, P., and Kappler, J. (2001) Immunity 14, 513-522
53. Rudolph, M. G., Speir, J. A., Brunmark, A., Mattsson, N., Jackson, M. R., Peterson, P. A., Teyton, L., and Wilson, I. A. (2001) Immunity 14, 231-242
54. Stoneman, E. R., Bennett, M., An, J., Chesnut, K. A., Wakeland, E. K., Scheerer, J. B., Siciliano, M. J., Kumar, V., and Mathew, P. A. (1995) J. Exp. Med. 182, 305-313
55. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins 11, 281-296
56. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. Deng, S. Cho, E. L. Malchiodi, M. C. Kerzic, J. Dam, and R. A. Mariuzza
Molecular Architecture of the Major Histocompatibility Complex Class I-binding Site of Ly49 Natural Killer Cell Receptors
J. Biol. Chem., June 13, 2008; 283(24): 16840 - 16849.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. K. Kaiser, J. C. Pizarro, J. Kerns, and R. K. Strong
Structural basis for NKG2A/CD94 recognition of HLA-E
PNAS, May 6, 2008; 105(18): 6696 - 6701.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. J. Lavender, H. H. Chau, and K. P. Kane
Distinctive Interactions at Multiple Site 2 Subsites by Allele-Specific Rat and Mouse Ly49 Determine Functional Binding and Class I MHC Specificity
J. Immunol., November 15, 2007; 179(10): 6856 - 6866.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. A. Benoit and R. Tan
Xenogeneic beta2-Microglobulin Substitution Affects Functional Binding of MHC Class I Molecules by CD8+ T Cells
J. Immunol., September 15, 2007; 179(6): 3588 - 3595.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. J. Adams, Z. S. Juo, R. T. Venook, M. J. Boulanger, H. Arase, L. L. Lanier, and K. C. Garcia
Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors
PNAS, June 12, 2007; 104(24): 10128 - 10133.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Back, A. Chalifour, L. Scarpellino, and W. Held
Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell/target cell contact
PNAS, March 6, 2007; 104(10): 3978 - 3983.
[Abstract] [Full Text]